Karen Liu

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China. To learn more about Biosion visit www.biosion.com.

Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The unique and proprietary technology owned by Dermaliq, called hyliQTM, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of superior, highly effective liquid drug products with exceptional cosmetic properties.

Neural Galaxy, a global leading brain science company. Jointly founded in July 2019 by Professor Hesheng Liu of Harvard Medical School, Guoping Feng and Robert Desimone at MIT, and Mr. Coach Wei. Neural Galaxy's mission is to solve brain disorders. Neural Galaxy announced its $6.2M Angel round financing and over $15M Pre-A round financing. With plus rounds and the A round financing over $75M, the startup has raised more than approximate $100M. Neural Galaxy has successfully solved a significant neuroscience challenge. It has developed the world's first and the only “personalized Brain Functional Sectors” technology (pBFS), reliably and accurately mapping over 200 functional parcellations of an individual brain. In 2020, Neural Galaxy released the world's first "Personalized Brain Computing Platform", enabling doctors to investigate individual-level brain functional issues from observing neural circuits and neural networks clinically for the first time. Its innovative therapy, POINT therapy, achieved individual-level precise intervention of brain disorder with a non-invasive "brain-computer interaction" approach to read, decode and write brain signals. Neural Galaxy has achieved significant positive treatment outcomes in several major brain diseases such as Depression, Alzheimer's disease, Parkinson's disease, Autism, and Aphasia through clinical trials jointly carried out with several top-tier hospitals.

Shanton Pharma is a clinical-stage biotech company founded in 2016, with a research focus on the unmet needs associated with gout, hyperuricemia, and pruritus. Our team focuses its resources on these important therapeutic areas through advanced and innovative drug research and developmental approaches.

Rapafusyn Pharmaceuticals is an emerging pharmaceutical development company located in Baltimore Maryland. Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from Johns Hopkins University School of Medicine and seeks to develop novel pharmaceuticals to treat patients having diseases and fulfill unmet medical needs.

Biologicals and small molecule development to target key ectonucleotidases for treatment of cancer, autoimmunity, inflammatory disease and metabolic syndrome

Avirmax, Inc. based in San Francisco Bay Area, is dedicated to innovate, develop and manufacture adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and BAC-to-AAV technologies. Avirmax Adeno-associated Vector Innovation Platform (AAVIP), enables us to become a “powerhouse” of rAAV therapeutics for its very infectious AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with the effective, safe, long-acting AAV-mediated biotherapeutics at the most affordable and accessible manner. Avirmax, Inc is dedicated to innovate and develop novel technologies to address current challenges in viral vector production based on its state of the art AAV bioprocess technologies in combination with Virovek’s BAC-to-AAV insect system. Avirmax has established robust rAAV vector production technologies for small and large-scale applications using Sf9-Baculovirus system.

Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.

Quadriga BioSciences, Inc. is a privately-held pharmaceutical company developing proprietary targeted cancer therapies. Our technology is based on the discovery that many aggressive forms of cancer cells over-express certain unique amino acid transporters on their cell surfaces for the intake of nutrients to support rapid tumor growth and proliferation. Exploiting this biology, Quadriga is developing novel targeted molecules against cancer cells that over-express these transporters. Our mission is to develop safer and more effective treatments for patients with cancer.

Aravive, Inc. is a late clinical-stage oncology company developing transformative, targeted therapeutics to treat metastatic disease. The company is based in Houston, Texas, and has a satellite office in the Research Triangle Park area in NC. For more information, please visit our website at http://www.aravive.com. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Dr. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer’s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.

Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function.

Profusa’s mission is to make our body’s chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status. We are leading the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Our technology enables the development of bioengineered sensors that become one with the body to detect and continuously transmit actionable, medical-grade data for personal and medical use. Profusa’s first clinical offering, the Lumee Oxygen Platform™, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. It may be used in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery. Any questions? Please visit profusa.com or email us at info@profusa.com

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China. To learn more about Biosion visit www.biosion.com.

Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The unique and proprietary technology owned by Dermaliq, called hyliQTM, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of superior, highly effective liquid drug products with exceptional cosmetic properties.

Neural Galaxy, a global leading brain science company. Jointly founded in July 2019 by Professor Hesheng Liu of Harvard Medical School, Guoping Feng and Robert Desimone at MIT, and Mr. Coach Wei. Neural Galaxy's mission is to solve brain disorders. Neural Galaxy announced its $6.2M Angel round financing and over $15M Pre-A round financing. With plus rounds and the A round financing over $75M, the startup has raised more than approximate $100M. Neural Galaxy has successfully solved a significant neuroscience challenge. It has developed the world's first and the only “personalized Brain Functional Sectors” technology (pBFS), reliably and accurately mapping over 200 functional parcellations of an individual brain. In 2020, Neural Galaxy released the world's first "Personalized Brain Computing Platform", enabling doctors to investigate individual-level brain functional issues from observing neural circuits and neural networks clinically for the first time. Its innovative therapy, POINT therapy, achieved individual-level precise intervention of brain disorder with a non-invasive "brain-computer interaction" approach to read, decode and write brain signals. Neural Galaxy has achieved significant positive treatment outcomes in several major brain diseases such as Depression, Alzheimer's disease, Parkinson's disease, Autism, and Aphasia through clinical trials jointly carried out with several top-tier hospitals.

Shanton Pharma is a clinical-stage biotech company founded in 2016, with a research focus on the unmet needs associated with gout, hyperuricemia, and pruritus. Our team focuses its resources on these important therapeutic areas through advanced and innovative drug research and developmental approaches.

Rapafusyn Pharmaceuticals is an emerging pharmaceutical development company located in Baltimore Maryland. Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from Johns Hopkins University School of Medicine and seeks to develop novel pharmaceuticals to treat patients having diseases and fulfill unmet medical needs.